Gilead Sciences bolstered its in vivo cell therapy capabilities through the $350 million acquisition of Interius BioTherapeutics. This move positions Gilead as a significant player in the emerging field of single-shot, in vivo CAR-T therapies, which aim to genetically modify immune cells within the patient’s body, offering potential improvements in scalability, safety, and accessibility compared to ex vivo approaches. With CAR-T therapies revolutionizing oncology, particularly hematologic malignancies, this acquisition intensifies competition and innovation in next-generation cell-based immunotherapies.